AnaptysBio (NASDAQ:ANAB) Issues Earnings Results, Beats Expectations By $0.89 EPS

AnaptysBio (NASDAQ:ANAB) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.61) by $0.89, Zacks reports. The business had revenue of $43.11 million for the quarter, compared to analyst estimates of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%.

AnaptysBio Trading Up 2.6 %

NASDAQ ANAB opened at $16.82 on Friday. The stock’s fifty day moving average price is $16.01 and its 200-day moving average price is $24.71. AnaptysBio has a 12 month low of $12.21 and a 12 month high of $41.31. The stock has a market cap of $511.82 million and a P/E ratio of -2.77.

Analyst Ratings Changes

A number of research analysts have commented on ANAB shares. Truist Financial lowered their price target on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Wolfe Research started coverage on AnaptysBio in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $25.00 price target for the company. HC Wainwright reissued a “neutral” rating and set a $19.00 price objective on shares of AnaptysBio in a research report on Tuesday, February 4th. Wedbush reaffirmed an “outperform” rating and issued a $40.00 target price on shares of AnaptysBio in a research report on Wednesday, February 12th. Finally, BTIG Research cut shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, AnaptysBio has an average rating of “Moderate Buy” and an average target price of $34.11.

Insider Buying and Selling

In related news, Director Ecor1 Capital, Llc purchased 6,646 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was purchased at an average price of $12.95 per share, with a total value of $86,065.70. Following the completion of the purchase, the director now owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. The trade was a 0.08 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 33.70% of the stock is currently owned by company insiders.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.